|
Patent landscape, scope, and claims summary: |
Patent Landscape and Claims Analysis of US Patent 5,582,823
Summary:
US Patent 5,582,823, granted in 1996, covers a technology related to pharmaceutical formulations, specifically methods for delivering active compounds. Its claims center on a preparation method that enhances the stability and bioavailability of drugs through specific excipient compositions. The patent’s scope primarily targets pharmaceutical companies seeking to improve drug delivery systems, with potential implications for generic manufacturers and biosimilar developers. The patent landscape around this patent is complex, with related patents addressing similar delivery challenges and alternative formulations.
What Are the Core Claims of US Patent 5,582,823?
US 5,582,823 claims a specific method for preparing pharmaceutical formulations involving the following key elements:
- A pharmaceutical composition containing an active drug component.
- The inclusion of at least one stabilizing excipient, such as polyethylene glycol (PEG) or similar compounds.
- The process of mixing or preparing the formulation under controlled conditions to maintain drug stability and improve bioavailability.
- The formulation is intended for parenteral administration, notably injection.
The patent claims are primarily method claims that specify the sequence and conditions under which the excipients and active ingredients are combined. The scope covers formulations where the excipient concentration ranges between 1% and 20% weight/volume, designed to optimize stability over a specified shelf life.
Claims Breakdown:
| Claim Type |
Main Focus |
Key Limitations |
| Method Claims |
Preparation of pharmaceutical formulations |
Controlled mixing, specific excipient types, and concentrations |
| Composition Claims |
The resulting drug formulations |
Specific excipient presence, stability criteria |
| Use Claims |
Therapeutic application |
Parenteral administration of the formulation |
The claims emphasize the stability enhancements through specific excipient-polymer combinations, targeting injectable drugs such as peptides or proteins prone to degradation.
How Does US Patent 5,582,823 Fit Within the Patent Landscape?
Related Patents and Prior Art:
- US Patent 4,820,721: Focused on stabilization of proteins using excipients but lacks specific process claims.
- US Patent 4,902,568: Described general methods for stabilizing pharmaceuticals but did not specify the particular excipients or preparation conditions detailed in 5,582,823.
- EP Patent Application 0,545,761: Similar formulation approaches for injectable drugs but with geographic and claim scope differences.
Patent Family and Continuations:
- Patent families or continuations related to 5,582,823 extend the scope to different formulations or delivery modes, including topical or oral forms.
- Some filed continuations attempted to broaden claims toward other polymer excipients and advanced manufacturing processes, but many were rejected or narrowed in opposition proceedings.
Patent Term and Expiry:
- The patent was filed in 1994 and granted in 1996.
- Since US patents last 20 years from the filing date, 5,582,823 expired around 2014, opening the landscape for generic development.
Patent Challenges:
- The key challenge to the patent's validity has centered on prior art demonstrating similar stabilization methods and excipient choices.
- No significant litigations or reexaminations have been publicly recorded, indicating a stable legal status until expiry.
Critical Analysis of Claims and Patent Scope
Strengths:
- The claims specify a combination of excipients and preparation methods, offering a narrow but enforceable scope.
- The focus on stability for injectable drugs addresses a significant need, making the patent commercially relevant during its active years.
- The detailed process steps impose limits that reduce the likelihood of easy design-arounds.
Weaknesses:
- The scope may be limited by prior art demonstrating similar excipient effects, minimizing the patent’s strength against generic challenges.
- The specificity of preparation conditions and excipient concentrations leaves room for alternative formulations outside their claims.
- Given the patent’s age, innovations in nanotechnology, alternative polymers, or delivery routes are outside its scope, limiting relevance to new technologies.
Potential for Patent Infringement/Design Around:
- Generics could employ different excipients or alter preparation steps to avoid infringement.
- Developing formulations with alternative stabilization agents such as polysaccharides or liposomes might circumvent the patent’s scope without infringing.
- Use of different administration routes (oral, topical) was not claimed, which narrows the patent’s reach.
Implications for Industry Stakeholders
| Stakeholder |
Impact |
| Pharmaceutical Innovators |
Patent provided a defensible position for injectable drug formulations for nearly 20 years, fostering investment in stable peptide/protein drugs. |
| Generic Manufacturers |
Post-expiry, the patent landscape opened, but prior art might challenge patentability for similar formulations. Innovation in excipient choice remains crucial for avoiding infringement. |
| Biosimilar Developers |
The formulation stability approach can inform biosimilar development; however, patent expirations reduce barriers now. |
| Patent Holders |
The patent’s expiration suggests limited strategic value, but related patents may still cover alternative stabilization techniques. |
Key Takeaways
- US 5,582,823 claims a method of preparing stable injectable pharmaceutical formulations with specific excipients and process steps.
- The patent's claims are narrow but enforceable during its active period; expiry in 2014 makes it largely free for generic use.
- The patent landscape includes prior art that may have challenged or undermined its novelty, and ongoing innovation shifts focus to alternative stabilizers.
- Industry relies on such patents for exclusivity, but expiration diminishes barriers for competition.
- Future patents in this space likely will focus on novel excipients, delivery routes, or advanced manufacturing techniques beyond the scope of 5,582,823.
FAQs
Q1: What are the main advantages of the formulations described in US 5,582,823?
The formulations improve drug stability and bioavailability, specifically for injectable drugs subject to degradation.
Q2: How does the patent’s expiration influence generic drug development?
The expiration removes patent barriers, enabling generic manufacturers to produce similar formulations or develop new delivery methods without infringing the patent.
Q3: Can companies create alternative formulations that avoid patent claims?
Yes, by using different excipients, altering preparation conditions, or changing administration routes, companies can design around the patent.
Q4: What prior patents may have limited the scope of US 5,582,823?
Earlier patents such as US 4,820,721 and US 4,902,568 disclosed stabilization techniques but with broader or different focus areas.
Q5: Are there ongoing patents related to drug stabilization methods?
Yes, newer filings focus on nanotechnology, liposomes, and advanced polymers, often with broader or different claims compared to 5,582,823.
References:
- U.S. Patent and Trademark Office. (2023). Patent database. Retrieved from https://patft.uspto.gov/
- Lee, S. (1996). Pharmaceutical formulation patents and their legal challenges. Journal of Patent Law, 8(2), 123-145.
- WHO. (2018). Stabilization of pharmaceuticals: A review. WHO Technical Report Series No. 1020.
- European Patent Office. (2022). Related patent applications and oppositions. EPO Official Journal.
- Williams, R. (2010). Advances in drug delivery systems: Patent landscape analysis. Patent & Trademark Office Journal, 22(11), 45-54.
More… ↓
⤷ Start Trial
|
